Imagen de Portada

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real‐World Evidence

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Rohini K. Hernandez, Cathy W. Critchlow, Nancy Dreyer, Timothy L. Lash, Robert F. Reynolds, Henrik T. Sørensen, Jeff L. Lange, Nicolle M. Gatto, Rachel E. Sobel, Edward Chia‐Cheng Lai, Marieke Schoonen, Jeffrey S. Brown, Jennifer B. Christian, M. Alan Brookhart, Brian D. Bradbury
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Dawning Era of Anticancer Nanomedicines: From First Principles to Application of Silk Nanoparticles
por: Saphia A. L. Matthew, et al.
Publicado: (2024)

Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review
por: Marieke S. Jansen, et al.
Publicado: (2024)

MicroRNA‐145 in Breast Cancer: Unravelling Its Multifaceted Regulatory Roles and Translational Perspectives
por: Chu Xin Ng, et al.
Publicado: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
por: J. Couch, et al.
Publicado: (2025)

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
por: Anna M. G. Pasmooij, et al.
Publicado: (2024)

Pharmacoepidemiology
Publicado: (2023)

The Use of Real‐World Evidence for Regulatory Decisions in China
por: Jiayue Xu, et al.
Publicado: (2024)

Regulatory Issues of Platform Trials: Learnings from EU‐PEARL
por: Quynh Lan Nguyen, et al.
Publicado: (2024)

Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
por: Atiqur Rahman, et al.
Publicado: (2024)

From Challenge to Opportunity: How Shwachman–Diamond Syndrome Became a Promising Target for Therapy Development
por: Eszter S. Hars, et al.
Publicado: (2024)

Immuno‐Engineering in the AI Era: From Fundamental Research to Clinical Translation
por: Meng Zhu, et al.
Publicado: (2025)

Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic Review
por: Bonginkosi S'fiso Ndzamba, et al.
Publicado: (2024)

Real‐World Evidence in Regulatory Decision Making: Time for Evidence Integration
por: Rebecca A. Miksad
Publicado: (2024)

Inhalational Delivery of β‐glucan‐chitosan‐poly(lactic co‐glycolic) acid Nanoparticles Enhance Alveolar Macrophage Rifampin Concentrations for the Treatment of Tuberculosis
por: Hilliard L. Kutscher, et al.
Publicado: (2024)

Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System
por: Neil S. Zheng, et al.
Publicado: (2025)

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network
por: Priya Jayachandran, et al.
Publicado: (2026)

Regulatory Interactions and Learnings— RADIAL the Trials@Home Proof‐of‐Concept Trial on Decentralization
por: Helga Gardarsdottir, et al.
Publicado: (2025)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
por: Mohamed A. Kamal, et al.
Publicado: (2024)

Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals
por: Noah C. Neverette, et al.
Publicado: (2024)

Sirtuin1 in Spinal Cord Injury: Regulatory Mechanisms, Microenvironment Remodeling and Therapeutic Potential
por: Jinze Li, et al.
Publicado: (2025)

Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis
por: Seonji Kim, et al.
Publicado: (2025)

Regulatory Perspective Based on Survey of Relationship Between Biopharmaceutical Characteristics and Food Effects on Systemic Pharmacokinetics
por: Naoko Honma, et al.
Publicado: (2025)

Characteristics of Drugs from Non‐Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval
por: Kensuke Matsuda, et al.
Publicado: (2024)

Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan
por: Kensuke Matsuda, et al.
Publicado: (2025)

The Rare Disease Moonshot: Paradigms Shift, Translational Medicine, and Regulatory Science for the World's Rarest Conditions
por: Cécile Ollivier, et al.
Publicado: (2024)

Corrections to “Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions”
Publicado: (2024)

Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Publicado: (2024)

NLRP3 Inflammasome in Vascular Dementia: Regulatory Mechanisms, Functions, and Therapeutic Implications: A Comprehensive Review
por: Yujia Lu, et al.
Publicado: (2025)

Capability Development in the European Medicines Regulatory Network—A European Learning Needs Analysis and Survey Study
por: Naomi Beard, et al.
Publicado: (2025)

Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors
por: Jessie P. Bakker, et al.
Publicado: (2024)

The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency
por: Elodie Baumfeld Andre, et al.
Publicado: (2024)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
por: Maxim S. Petrov
Publicado: (2026)

Overall adherence in hemodialysis patients and associated factors: A cross‐sectional study from Morocco
por: L. Mazzi, et al.
Publicado: (2024)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance
por: Apichat Kaewdech, et al.
Publicado: (2026)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
por: Xiaoyu Men, et al.
Publicado: (2024)

Identification of Schizophrenia‐Risk Regulatory Variant rs1399178 in the Non‐coding Region With Its Impact on NRF1 Binding
por: Lei Ji, et al.
Publicado: (2025)

Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)
por: Dahee Jung, et al.
Publicado: (2025)

Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
por: Nisha Sharma, et al.
Publicado: (2024)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
por: Christopher L. Bowlus, et al.
Publicado: (2025)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
por: Michelle Spaan, et al.
Publicado: (2026)